Prothena Corp (PRTA)

$9.13 +0.16 (1.78%)
Market Cap 495.24M
Revenue (ttm) 135.16M
Net Income (ttm) -122.31M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 47.28
Profit Margin -90.49%
Debt to Equity Ratio 0.00
Volume 468,600
Avg Vol 660,402
Day's Range N/A - N/A
Shares Out 53.83M
Stochastic %K 29%
Beta -0.09
Analysts Sell
Price Target $20.33

Company Profile

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. Its product pipeline include Prasinezumab, an investigational humanized monoclonal antibody which is in phase 2b clinical trial, as well as phase 1 and 2 clinical trials for the treatment of parkinson's disease and other synucleinopathies. The company also develops Coramitug, an investigational antib...

Industry: Biotechnology
Sector: Healthcare
Phone: 353 1 236 2500
Fax: 353 1 902 3510
Address:
77 Sir John Rogerson’s Quay, Block C Grand Canal Docklands, Dublin, Ireland
buyandsold
buyandsold Jan. 2 at 12:36 PM
$PRTA let's retake $11 in January as funds load up for sales of some assets with special dividends to follow.
1 · Reply
PaperWalletP4
PaperWalletP4 Dec. 26 at 4:23 PM
$PRTA Capital is flowing toward execution strength rather than speculative optionality. Forecast discipline should become more precise and conservative. Sustained traction could validate the investment case. Upside remains tied to tangible progress, not assumptions.
0 · Reply
KurtosisKing
KurtosisKing Dec. 24 at 12:28 PM
$PRTA Sentiment could pivot sharply depending on how strategic priorities translate into measurable operating outcomes. Delays or dilution could materially reshape the risk profile.
1 · Reply
AIIAAIIA_88
AIIAAIIA_88 Dec. 19 at 8:57 PM
$PRTA Year end tax loss sells? Disgusting. Very disgusting. LOL
0 · Reply
buyandsold
buyandsold Dec. 17 at 11:05 PM
$PRTA brutality writ large Management should throw us a buyback bone
0 · Reply
AIIAAIIA_88
AIIAAIIA_88 Dec. 17 at 1:27 AM
$PRTA Someone is expecting pretty bad news soon. Hmm. I am more bullish. LOL
0 · Reply
buyandsold
buyandsold Dec. 16 at 3:18 PM
$PRTA tought to buy at $11 and be here a week later!
0 · Reply
AIIAAIIA_88
AIIAAIIA_88 Dec. 16 at 2:16 AM
$PRTA Unusually high AH volume buys today. JMO
2 · Reply
AIIAAIIA_88
AIIAAIIA_88 Dec. 12 at 10:09 PM
$PRTA The usual Friday strength regardless of the overall market condition over the recent weeks tells me it is getting close! Just saying! LFG 🔥🚀🔥🚀🔥🚀🔥🚀🔥🚀🔥🚀🔥🚀🔥🚀🔥🚀🔥🚀🔥🚀🔥🚀🔥🚀🔥🚀🔥🚀🔥🚀🔥🚀🔥🚀🔥🚀🔥🚀🔥🚀
0 · Reply
Quantumup
Quantumup Dec. 10 at 2:04 PM
H.C. Wainwright y'day⬆️ $IMMX's PT to $12 from $8, plus⬆️PoS to 85% and reiterated at a Buy rating. $PRTA $AZN $JNJ ABBV $TAK BMY SNY Here's what H.C. Wainwright said in its note: https://x.com/Quantumup1/status/1998754299422122357?s=20
0 · Reply
Latest News on PRTA
Prothena Announces Board of Directors Update

Dec 12, 2025, 4:05 PM EST - 26 days ago

Prothena Announces Board of Directors Update

Prothena Announces Poster Presentation on its TDP-43 CYTOPE® Program at Neuroscience 2025

Nov 19, 2025, 4:05 PM EST - 7 weeks ago

Prothena Announces Poster Presentation on its TDP-43 CYTOPE® Program at Neuroscience 2025

Prothena Highlights Phase 2 Data for Coramitug (Formerly PRX004) Published in Circulation, Official Journal of AHA

Nov 11, 2025, 9:00 AM EST - 2 months ago

Prothena Highlights Phase 2 Data for Coramitug (Formerly PRX004) Published in Circulation, Official Journal of AHA

Prothena Reports Third Quarter 2025 Financial Results and Business Highlights

Nov 6, 2025, 4:05 PM EST - 2 months ago

Prothena Reports Third Quarter 2025 Financial Results and Business Highlights

Prothena to Report Third Quarter 2025 Financial Results on November 6

Oct 30, 2025, 4:05 PM EDT - 2 months ago

Prothena to Report Third Quarter 2025 Financial Results on November 6

Prothena's Partner Bristol Myers Squibb Obtains Fast Track Designation from the U.S. FDA for BMS-986446 (PRX005), an Anti-MTBR-Tau-Targeting Antibody, for the Treatment of Alzheimer's Disease

Oct 1, 2025, 4:45 PM EDT - 3 months ago

Prothena's Partner Bristol Myers Squibb Obtains Fast Track Designation from the U.S. FDA for BMS-986446 (PRX005), an Anti-MTBR-Tau-Targeting Antibody, for the Treatment of Alzheimer's Disease

Prothena to Participate in the Cantor Fitzgerald Global Healthcare Conference

Aug 28, 2025, 4:05 PM EDT - 4 months ago

Prothena to Participate in the Cantor Fitzgerald Global Healthcare Conference

Prothena Provides Update on PRX012 and Announces Results from the Phase 1 ASCENT Clinical Program

Aug 27, 2025, 4:05 PM EDT - 4 months ago

Prothena Provides Update on PRX012 and Announces Results from the Phase 1 ASCENT Clinical Program

Prothena Announces that Novo Nordisk Will Advance Coramitug (Formerly PRX004) into Phase 3 Development for ATTR Amyloidosis with Cardiomyopathy

Aug 6, 2025, 9:00 AM EDT - 5 months ago

Prothena Announces that Novo Nordisk Will Advance Coramitug (Formerly PRX004) into Phase 3 Development for ATTR Amyloidosis with Cardiomyopathy

Prothena Reports Second Quarter 2025 Financial Results and Business Highlights

Aug 4, 2025, 4:05 PM EDT - 5 months ago

Prothena Reports Second Quarter 2025 Financial Results and Business Highlights

Prothena to Report Second Quarter 2025 Financial Results on August 4

Jul 28, 2025, 4:05 PM EDT - 5 months ago

Prothena to Report Second Quarter 2025 Financial Results on August 4

Prothena Announces Corporate Restructuring

Jun 18, 2025, 4:05 PM EDT - 7 months ago

Prothena Announces Corporate Restructuring

Prothena's Partner Roche to Advance Prasinezumab into Phase III Development for Early-Stage Parkinson's Disease

Jun 16, 2025, 1:06 AM EDT - 7 months ago

Prothena's Partner Roche to Advance Prasinezumab into Phase III Development for Early-Stage Parkinson's Disease

Why Is Prothena Stock Trading Lower On Tuesday?

May 27, 2025, 7:43 AM EDT - 8 months ago

Why Is Prothena Stock Trading Lower On Tuesday?

Prothena Announces Phase 3 AFFIRM-AL Clinical Trial for Birtamimab in Patients with AL Amyloidosis Did Not Meet Primary Endpoint

May 23, 2025, 4:05 PM EDT - 8 months ago

Prothena Announces Phase 3 AFFIRM-AL Clinical Trial for Birtamimab in Patients with AL Amyloidosis Did Not Meet Primary Endpoint

Top 3 Health Care Stocks That Are Preparing To Pump This Quarter

May 9, 2025, 7:16 AM EDT - 8 months ago

Top 3 Health Care Stocks That Are Preparing To Pump This Quarter

RXST SRPT

Prothena Reports First Quarter 2025 Financial Results and Business Highlights

May 8, 2025, 4:05 PM EDT - 8 months ago

Prothena Reports First Quarter 2025 Financial Results and Business Highlights

Prothena to Report First Quarter 2025 Financial Results on May 8

May 1, 2025, 4:05 PM EDT - 8 months ago

Prothena to Report First Quarter 2025 Financial Results on May 8

Prothena Corporation plc (PRTA) Q4 2024 Earnings Call Transcript

Feb 20, 2025, 8:45 PM EST - 11 months ago

Prothena Corporation plc (PRTA) Q4 2024 Earnings Call Transcript

Prothena Reports Fourth Quarter and Full Year 2024 Financial Results, and Provides Financial Guidance and Business Highlights

Feb 20, 2025, 4:05 PM EST - 11 months ago

Prothena Reports Fourth Quarter and Full Year 2024 Financial Results, and Provides Financial Guidance and Business Highlights

Kuehn Law Encourages Investors of Prothena Corporation PLC to Contact Law Firm

Feb 17, 2025, 6:10 PM EST - 11 months ago

Kuehn Law Encourages Investors of Prothena Corporation PLC to Contact Law Firm

Prothena to Report Fourth Quarter and Full Year 2024 Financial Results on February 20, 2025

Feb 13, 2025, 4:05 PM EST - 11 months ago

Prothena to Report Fourth Quarter and Full Year 2024 Financial Results on February 20, 2025

Roche's Phase IIb Study of Prasinezumab Missed Primary Endpoint, But Suggests Possible Clinical Benefit in Early-Stage Parkinson's Disease

Dec 19, 2024, 1:05 AM EST - 1 year ago

Roche's Phase IIb Study of Prasinezumab Missed Primary Endpoint, But Suggests Possible Clinical Benefit in Early-Stage Parkinson's Disease

Prothena Reports Third Quarter 2024 Financial Results and Business Highlights

Nov 12, 2024, 4:05 PM EST - 1 year ago

Prothena Reports Third Quarter 2024 Financial Results and Business Highlights

Prothena to Report Third Quarter 2024 Financial Results on November 12

Nov 5, 2024, 4:05 PM EST - 1 year ago

Prothena to Report Third Quarter 2024 Financial Results on November 12

Prothena Announces Leadership Team Updates

Sep 27, 2024, 4:05 PM EDT - 1 year ago

Prothena Announces Leadership Team Updates

Prothena to Participate in Upcoming Healthcare Conferences

Aug 29, 2024, 4:05 PM EDT - 1 year ago

Prothena to Participate in Upcoming Healthcare Conferences

Prothena Reports Second Quarter 2024 Financial Results and Business Highlights

Aug 8, 2024, 4:05 PM EDT - 1 year ago

Prothena Reports Second Quarter 2024 Financial Results and Business Highlights

Prothena to Report Second Quarter 2024 Financial Results on August 8

Aug 1, 2024, 4:05 PM EDT - 1 year ago

Prothena to Report Second Quarter 2024 Financial Results on August 8

Prothena Announces Bristol Myers Squibb Opt-in for Exclusive Global License for PRX019, the Second Program from Global Neuroscience Research and Development Collaboration

May 28, 2024, 4:05 PM EDT - 1 year ago

Prothena Announces Bristol Myers Squibb Opt-in for Exclusive Global License for PRX019, the Second Program from Global Neuroscience Research and Development Collaboration

Prothena Reports First Quarter 2024 Financial Results and Business Highlights

May 8, 2024, 4:05 PM EDT - 1 year ago

Prothena Reports First Quarter 2024 Financial Results and Business Highlights

Prothena to Report First Quarter 2024 Financial Results on May 8

May 1, 2024, 4:05 PM EDT - 1 year ago

Prothena to Report First Quarter 2024 Financial Results on May 8

Prothena Announces Review on Birtamimab Mechanism of Action and Pharmacological Characteristics Published in Leukemia & Lymphoma

Apr 15, 2024, 4:05 PM EDT - 1 year ago

Prothena Announces Review on Birtamimab Mechanism of Action and Pharmacological Characteristics Published in Leukemia & Lymphoma

Prothena Appoints David Ford to Newly Created Chief People Officer Position

Mar 4, 2024, 4:05 PM EST - 2 years ago

Prothena Appoints David Ford to Newly Created Chief People Officer Position

Prothena: Alzheimer's Data Update In 2024 Could Move The Needle

Feb 23, 2024, 12:31 PM EST - 2 years ago

Prothena: Alzheimer's Data Update In 2024 Could Move The Needle

Prothena Announces Appointment of Daniel G. Welch as Director and Chair Designate

Feb 21, 2024, 4:05 PM EST - 2 years ago

Prothena Announces Appointment of Daniel G. Welch as Director and Chair Designate

Prothena Corporation plc (PRTA) Q4 2023 Earnings Call Transcript

Feb 15, 2024, 11:53 PM EST - 2 years ago

Prothena Corporation plc (PRTA) Q4 2023 Earnings Call Transcript

Prothena Reports Fourth Quarter and Full Year 2023 Financial Results, and Provides Financial Guidance and Business Highlights

Feb 15, 2024, 4:05 PM EST - 2 years ago

Prothena Reports Fourth Quarter and Full Year 2023 Financial Results, and Provides Financial Guidance and Business Highlights

Prothena to Report Fourth Quarter and Full Year 2023 Financial Results on February 15, 2024

Feb 8, 2024, 4:05 PM EST - 2 years ago

Prothena to Report Fourth Quarter and Full Year 2023 Financial Results on February 15, 2024

Prothena Provides Updates on PRX012, PRX123, Birtamimab and Portfolio Programs

Jan 8, 2024, 8:30 AM EST - 2 years ago

Prothena Provides Updates on PRX012, PRX123, Birtamimab and Portfolio Programs

Prothena Reports Third Quarter 2023 Financial Results and Business Highlights

Nov 2, 2023, 4:05 PM EDT - 2 years ago

Prothena Reports Third Quarter 2023 Financial Results and Business Highlights

Prothena to Report Third Quarter 2023 Financial Results on November 2

Oct 26, 2023, 4:05 PM EDT - 2 years ago

Prothena to Report Third Quarter 2023 Financial Results on November 2

Prothena prepares for potential sale - Bloomberg News

Oct 16, 2023, 11:57 AM EDT - 2 years ago

Prothena prepares for potential sale - Bloomberg News

Prothena: Switching From 'Hold' To 'Buy' On Lead Alzheimer's Drug Promise

Sep 21, 2023, 1:39 PM EDT - 2 years ago

Prothena: Switching From 'Hold' To 'Buy' On Lead Alzheimer's Drug Promise

Prothena Reports Second Quarter 2023 Financial Results and Business Highlights

Aug 3, 2023, 4:05 PM EDT - 2 years ago

Prothena Reports Second Quarter 2023 Financial Results and Business Highlights

Prothena to Report Second Quarter 2023 Financial Results on August 3

Jul 27, 2023, 4:05 PM EDT - 2 years ago

Prothena to Report Second Quarter 2023 Financial Results on August 3

Prothena: Dunn Appointment And Bristol Opt-In Boost Validation

Jul 27, 2023, 7:23 AM EDT - 2 years ago

Prothena: Dunn Appointment And Bristol Opt-In Boost Validation

Prothena Presents New Research in the Treatment of Alzheimer's Disease at Alzheimer's Association International Conference® 2023 (AAIC®)

Jul 17, 2023, 8:35 AM EDT - 2 years ago

Prothena Presents New Research in the Treatment of Alzheimer's Disease at Alzheimer's Association International Conference® 2023 (AAIC®)

Prothena to Present New Data from Alzheimer's Disease Programs at Alzheimer's Association International Conference® 2023 (AAIC®)

Jul 11, 2023, 4:05 PM EDT - 2 years ago

Prothena to Present New Data from Alzheimer's Disease Programs at Alzheimer's Association International Conference® 2023 (AAIC®)

Prothena Announces Bristol Myers Squibb Opt-in for Worldwide Rights of PRX005, a Novel Anti-MTBR-Tau Antibody

Jul 10, 2023, 4:10 PM EDT - 2 years ago

Prothena Announces Bristol Myers Squibb Opt-in for Worldwide Rights of PRX005, a Novel Anti-MTBR-Tau Antibody

buyandsold
buyandsold Jan. 2 at 12:36 PM
$PRTA let's retake $11 in January as funds load up for sales of some assets with special dividends to follow.
1 · Reply
PaperWalletP4
PaperWalletP4 Dec. 26 at 4:23 PM
$PRTA Capital is flowing toward execution strength rather than speculative optionality. Forecast discipline should become more precise and conservative. Sustained traction could validate the investment case. Upside remains tied to tangible progress, not assumptions.
0 · Reply
KurtosisKing
KurtosisKing Dec. 24 at 12:28 PM
$PRTA Sentiment could pivot sharply depending on how strategic priorities translate into measurable operating outcomes. Delays or dilution could materially reshape the risk profile.
1 · Reply
AIIAAIIA_88
AIIAAIIA_88 Dec. 19 at 8:57 PM
$PRTA Year end tax loss sells? Disgusting. Very disgusting. LOL
0 · Reply
buyandsold
buyandsold Dec. 17 at 11:05 PM
$PRTA brutality writ large Management should throw us a buyback bone
0 · Reply
AIIAAIIA_88
AIIAAIIA_88 Dec. 17 at 1:27 AM
$PRTA Someone is expecting pretty bad news soon. Hmm. I am more bullish. LOL
0 · Reply
buyandsold
buyandsold Dec. 16 at 3:18 PM
$PRTA tought to buy at $11 and be here a week later!
0 · Reply
AIIAAIIA_88
AIIAAIIA_88 Dec. 16 at 2:16 AM
$PRTA Unusually high AH volume buys today. JMO
2 · Reply
AIIAAIIA_88
AIIAAIIA_88 Dec. 12 at 10:09 PM
$PRTA The usual Friday strength regardless of the overall market condition over the recent weeks tells me it is getting close! Just saying! LFG 🔥🚀🔥🚀🔥🚀🔥🚀🔥🚀🔥🚀🔥🚀🔥🚀🔥🚀🔥🚀🔥🚀🔥🚀🔥🚀🔥🚀🔥🚀🔥🚀🔥🚀🔥🚀🔥🚀🔥🚀🔥🚀
0 · Reply
Quantumup
Quantumup Dec. 10 at 2:04 PM
H.C. Wainwright y'day⬆️ $IMMX's PT to $12 from $8, plus⬆️PoS to 85% and reiterated at a Buy rating. $PRTA $AZN $JNJ ABBV $TAK BMY SNY Here's what H.C. Wainwright said in its note: https://x.com/Quantumup1/status/1998754299422122357?s=20
0 · Reply
SuperGreenToday
SuperGreenToday Dec. 9 at 5:59 PM
$PRTA Share Price: $10.53 Contract Selected: Jun 18, 2026 $10 Calls Buy Zone: $1.53 – $1.89 Target Zone: $2.65 – $3.23 Potential Upside: 63% ROI Time to Expiration: 190 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
AIIAAIIA_88
AIIAAIIA_88 Dec. 5 at 8:43 PM
$PRTA What is it with the short sellers and bears who cannot tolerate seeing this stock over $11 for a day??!! They will be kicking and crying soon enough. JMO
1 · Reply
AIIAAIIA_88
AIIAAIIA_88 Dec. 3 at 8:49 PM
https://stocktwits.com/news-articles/markets/equity/bristol-myers-stock-jumps-as-wall-street-backs-added-enrollment-in-alzheimer-s-trial/cLIXwRaRE1p This is with $PRTA drug candidate for AD. Incredible that the article does not mention $PRTA. But I know! This is why the stock is up almost 10% today.
1 · Reply
AIIAAIIA_88
AIIAAIIA_88 Dec. 3 at 2:42 PM
$PRTA Please be like CAPR soon. Very soon! 🔥🚀🔥🚀🔥🚀🔥🚀🔥🚀🔥🚀🔥
0 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Dec. 2 at 7:45 PM
$PROP $PRTA $PSCE $PSCI $PSCT Undeniable Accuracy Cycle Trading Signal plugged into AI 🔥 lists 🔥 Math don't lie 🔥
0 · Reply
AIIAAIIA_88
AIIAAIIA_88 Dec. 1 at 2:52 PM
$PRTA The AD + PD winner, I am sure of. Everyone thought that this one was dead earlier this year. Not by a long shot, nope. It is still alive and kicking! You will see very soon. JMO
0 · Reply
JarvisFlow
JarvisFlow Dec. 1 at 1:17 PM
Citizens updates rating for Prothena Corp ( $PRTA ) to Market Outperform, target set at 11 → 19.
0 · Reply
AIIAAIIA_88
AIIAAIIA_88 Nov. 26 at 3:20 PM
$PRTA AD and PD are graveyards for drug candidates so far. So many Big Pharmas like NVO, JNJ, and a little biotechs like SAVA, AVXL, ALEC, ANVS, BIVI, CGTX are all failing or has failed. BMY still has PRTA’s AD drug candidate in ongoing P2 and P1, and Roche still has P3 for PRTA’s drug candidates for PD. Besides, the amyloid protein buildup is now proven to be associated with aging! For longevity, one wants to rid of the amyloids buildup! This December will be awesome! LFG!! 🔥🚀🔥🚀🔥🚀🔥🚀🔥🚀
1 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Nov. 23 at 3:55 PM
$PROP $PRTA $PSCE $PSCI $PSCT 🔥
0 · Reply
buyandsold
buyandsold Nov. 22 at 2:38 AM
$PRTA this is 32% of my port, i would surely appreciate a $35 buyout on Monday
0 · Reply
AIIAAIIA_88
AIIAAIIA_88 Nov. 18 at 2:37 AM
$PRTA This biotech is already partnering with not one, not two, but three big pharma companies! BMY, NVO, RHHBY. Why chase others that keep promising partnerships that never materialize???? Beats me. LMAO
0 · Reply
AIIAAIIA_88
AIIAAIIA_88 Nov. 17 at 3:29 PM
$PRTA ANVS data are actually helping today. Tau protein in AD and PD research…. Although I do not trust ANVS, BMY will have great results with PRTA drug candidate. JMO
0 · Reply